Evolution of dupilumab-associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO-ADOC study).
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
17 Jul 2024
17 Jul 2024
Historique:
received:
25
01
2024
accepted:
24
05
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
17
7
2024
Statut:
aheadofprint
Résumé
Clinical trials and real-life data have reported an increased incidence of conjunctivitis in patients treated with dupilumab for their atopic dermatitis (AD). Although mostly mild in severity, in some cases conjunctivitis will appear or increase after dupilumab initiation, which can lead to dupilumab discontinuation. (1) To describe the characteristics of patients developing conjunctivitis requiring discontinuation of dupilumab; and (2) to analyse the factors associated with a complete conjunctivitis improvement after dupilumab discontinuation and a switch to tralokinumab or Janus kinase inhibitors. This was a multicentre retrospective cohort study that included all patients with AD treated with dupilumab who developed conjunctivitis leading to dupilumab discontinuation and switching to tralokinumab or Janus kinase inhibitors in daily practice. Data on patients, their AD and conjunctivitis were analysed at the inclusion visit (corresponding to discontinuation of dupilumab and the institution of new AD treatment), at visit 2 (3-6 months after inclusion) and at visit 3 (corresponding to the last medical visit). After multivariate analysis, the only factors associated with a complete resolution of dupilumab-associated conjunctivitis at visit 2 and/or visit 3 were conjunctivitis duration (OR 8.98, 95% CI 1.47-55) (p = 0.018), personal history of asthma (OR 10.66, 95% CI 1.82-62.63) (p = 0.009) and switching from dupilumab to Janus kinase inhibitors (OR 17.11, 95% CI 2.94-99.66) (p = 0.002). Although uncommon, severe dupilumab-associated conjunctivitis is more frequent in daily life compared to its incidence in the dupilumab pivotal trials. In these cases, our study suggests that a rapid switch to another molecule, particularly a Janus kinase inhibitor, should be considered.
Sections du résumé
BACKGROUND
BACKGROUND
Clinical trials and real-life data have reported an increased incidence of conjunctivitis in patients treated with dupilumab for their atopic dermatitis (AD). Although mostly mild in severity, in some cases conjunctivitis will appear or increase after dupilumab initiation, which can lead to dupilumab discontinuation.
OBJECTIVES
OBJECTIVE
(1) To describe the characteristics of patients developing conjunctivitis requiring discontinuation of dupilumab; and (2) to analyse the factors associated with a complete conjunctivitis improvement after dupilumab discontinuation and a switch to tralokinumab or Janus kinase inhibitors.
METHODS
METHODS
This was a multicentre retrospective cohort study that included all patients with AD treated with dupilumab who developed conjunctivitis leading to dupilumab discontinuation and switching to tralokinumab or Janus kinase inhibitors in daily practice. Data on patients, their AD and conjunctivitis were analysed at the inclusion visit (corresponding to discontinuation of dupilumab and the institution of new AD treatment), at visit 2 (3-6 months after inclusion) and at visit 3 (corresponding to the last medical visit).
RESULTS
RESULTS
After multivariate analysis, the only factors associated with a complete resolution of dupilumab-associated conjunctivitis at visit 2 and/or visit 3 were conjunctivitis duration (OR 8.98, 95% CI 1.47-55) (p = 0.018), personal history of asthma (OR 10.66, 95% CI 1.82-62.63) (p = 0.009) and switching from dupilumab to Janus kinase inhibitors (OR 17.11, 95% CI 2.94-99.66) (p = 0.002).
CONCLUSIONS
CONCLUSIONS
Although uncommon, severe dupilumab-associated conjunctivitis is more frequent in daily life compared to its incidence in the dupilumab pivotal trials. In these cases, our study suggests that a rapid switch to another molecule, particularly a Janus kinase inhibitor, should be considered.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : ResoMed
Informations de copyright
© 2024 European Academy of Dermatology and Venereology.
Références
Simpson EL, Bieber T, Guttman‐Yassky E, Beck LA, Blauvelt A, CorK MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348.
Akinlade B, Guttman‐Yassky E, de Bruin‐Weller M, Simpson EL, Blauvelt A, Cork MJ, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459–473.
Beck LA, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin‐Weller M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open‐label study of adults with moderate‐to‐severe atopic dermatitis. Am J Clin Dermatol. 2020;21(4):567–577.
Wollenberg A, Beck LA, de Bruin WM, Simpson EL, Imafuku S, Boguniewicz M, et al. Conjunctivitis in adult patients with moderate‐to‐severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022;186(3):453–465.
Simpson EL, Merola JF, Silverberg JI, Reich K, Warren BB, Staumont‐Salle D, et al. Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials. Br J Dermatol. 2022;187(6):888–899.
Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow‐up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol. 2022;158(4):404–413.
Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: a network meta‐analysis. Dermatol Ther. 2022;35(9):e15636.
Adam DN, Gooderham MJ, Beecker JR, Hong CH, Jack CS, Jain V, et al. Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol. 2023;37(6):1135–1148.
Costedoat I, Wallaert M, Gaultier A, Vasseur R, Vanhaecke C, Viguier M, et al. Multicenter prospective observational study of dupilumab‐induced ocular events in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2023;37(5):1056–1063.
Treister AD, Kraff‐Cooper C, Lio PA. Risk factors for dupilumab‐associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018;154(10):1208–1211.
Achten RE, Van Luijk C, Van der Rijst L, Bakker D, Spekhorst L, Zuithoff N, et al. Identification of risk factors for dupilumab‐associated ocular surface disease in patients with atopic dermatitis. Acta Derm Venereol. 2022;102:adv00666.
Olesen CM, Holm JG, Nørreslet LB, Serup JV, Thomsen SF, Agner T. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. J Eur Acad Dermatol Venereol. 2019;33(8):1562–1568.
Popiela M, Barbara R, Turnbull A, Corden E, Martinez‐Falero B, O'Driscoll D, et al. Dupilumab‐associated ocular surface disease: presentation, management, and long‐term sequelae. Eye (Lond). 2021;35(12):3277–3284.
Licata G, Tancredi V, Pezzolo E, Pertusi G, Tolino E, Arisi M, et al. Efficacy and safeness of tralokinumab in patients with atopic dermatitis who developed conjunctivitis under dupilumab: a case series. J Eur Acad Dermatol Venereol. 2023. https://doi.org/10.1111/jdv.19108. Epub Ahead of Print.
Gelato F, Mastorino L, Quaglino P, Cavaliere G, Ortoncelli M, Ribero S. Ocular adverse events in patients with atopic dermatitis treated with upadacitinib: a real‐life experience. Dermatitis. 2023;34(5):445–447.
Lasheras‐Pérez MA, Palacios‐Diaz RD, Pozuelo‐Ruiz M, Torres‐Navarro I, Botella‐Estrada R, Rodriguez‐Serna M. Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects. Int J Dermatol. 2023;63(1):105–107.
Achten R, Dekkers C, Bakker D, van Luijk C, de Graaf M, van Wijk F, et al. Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: preliminary case series. Clin Exp Allergy. 2023;53(5):586–589.
Doan S, Arnould L, Febvay C, Fournié P, Gueudry J, Labalette P, et al. Dupilumab‐related blepharoconjunctivitis: recommendations of the CEDRE group. Atopic dermatitis, conjunctivitis and dupilumab: which management approach? J Fr Ophtalmol. 2022;45(3):277–287.
Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, de Bruin‐Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate‐to‐severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047–1055.
Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate‐to‐severe atopic dermatitis: a randomised, double‐blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273–282.